bearing mice were injected with either PBS, 2.5 µg/g body weight rhodocetin-αβγδ in PBS, or 2 µg/g body weight rhodocetin-αβ in PBS. Within three hours, PBS injection (top) did not show any effect, whereas rhodocetin-αβγδ (middle) and its subunit rhodocetin-αβ (bottom) caused hemorrhage exclusively in tumor tissue. Representative images are shown.
shows a blood vessel surrounded by CD31-positive ECs (green).
Intravenously injected rhodocetin-αβ (red) was detectable on the surface of HT1080 tumor cells and on CD31
+ ECs (yellow colocalization signal). (B) fl uorescence intensity along a traceroute, averaged over a width of 5 pixels, (rectangle in a') through the blood vessel revealed that in ECs rhodocetin-αβ is not bound to their apical surface but rather to their basolateral side. Original magnifi cation was 400× (a-a'). Representative images are shown. by VE-cadherin negative and N-cadherin positive tumor cells. VE-cadherin is labeled in green and N-cadherin in red. (B) fl uorescence intensity of both signals along the dotted line marked in a' in clockwise direction and averaged over a width of fi ve pixels shows the absence of the VE-cadherin signal at the top vessel wall. C-C'', CD31-negative/PAS-positive VM vessels were visualized in tumor tissue by consecutive immunostaining and histochemical staining of the same cryosection: Normal CD31-positive blood vessels are labeled in green (C, C''), whereas CD31-negative VM vessels are detectable by PAS staining (C', C''). Nuclei are stained blue. Cryosections were fi rst immunostained and photographed (C), subsequently histochemically PAS-stained and photographed again (C'), and then the images were overlaid to demonstrate numerous CD31-negative/PAS-positive VM vessels (C'', arrows). Original magnifi cation was 400× (a-a') and 200× (C-C''). Representative images are shown.
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